Kriya Therapeutics has a total of 20 patents globally, out of which no patent have been granted. Of these 20 patents, more than 90% patents are active. Canada is where Kriya Therapeutics has filed the maximum number of patents, followed by Australia and Europe. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Kriya Therapeutics.
Kriya Therapeutics was founded in the year 2019. Kriya Therapeutics is a biopharmaceutical company that develops gene therapies for ophthalmology, neurology, and metabolic diseases.
Do read about some of the most popular patents of Kriya Therapeutics which have been covered by us in this article and also you can find Kriya Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Kriya Therapeutics patent portfolio.
How many patents does the founder and the CEO of Kriya Therapeutics have?
The founder Fraser Wright has 0 patent and Roger Jeffs has 0 patent and CEO Shankar Ramaswamy has 1 patent.
How many patents does Kriya Therapeutics have?
Kriya Therapeutics has a total of 20 patents globally. These patents belong to 6 unique patent families. Out of 20 patents, 18 patents are active.
How Many Patents did Kriya Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Kriya Therapeutics Applications Filed | Kriya Therapeutics Patents Granted |
| 2023 | 4 | – |
| 2022 | 6 | – |
| 2021 | 10 | – |
How many Kriya Therapeutics patents are Alive/Dead?
How Many Patents did Kriya Therapeutics File in Different Countries?
Countries in which Kriya Therapeutics Filed Patents
| Country | Patents |
| Canada | 3 |
| Australia | 2 |
| Europe | 2 |
| New Zealand | 1 |
| Mexico | 1 |
| Brazil | 1 |
| United States Of America | 1 |
| South Africa | 1 |
| Hong Kong (S.A.R.) | 1 |
| Israel | 1 |
Where are Research Centres of Kriya Therapeutics Patents Located?
The Research Centre for all the Kriya Therapeutics patents is the United States of America.
What Percentage of Kriya Therapeutics US Patent Applications were Granted?
Kriya Therapeutics (Excluding its subsidiaries) has filed 1 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 0 have been granted leading to a grant rate of 0.0%.
Below are the key stats of Kriya Therapeutics patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Kriya Therapeutics?
| Law Firm | Total Applications | Success Rate |
| Sterne Kessler Goldstein & Fox | 1 | 0% |
List of Kriya Therapeutics Patents
| Kriya Therapeutics Patents | Title |
| US20220162638A1 | Viral Vector Constructs For Delivery Of Nucleic Acids Encoding Cytokines And Uses Thereof For Treating Cancer |
| EP4228610A1 | Viral Vector Constructs For Delivery Of Nucleic Acids Encoding Cytokines And Uses Thereof For Treating Cancer |
| EP4176060A2 | Modified Insulin And Glucokinase Nucleic Acids For Treating Diabetes |
| WO2023133561A1 | Vector Constructs For Delivery Of Nucleic Acids Encoding Therapeutic Anti-Igf-1R Antibodies And Methods Of Using The Same |
| WO2022221462A1 | Vector Constructs For Delivery Of Nucleic Acids Encoding Therapeutic Vlcad Or Mcad And Methods Of Using The Same |
| WO2022187679A1 | Viral Vector Constructs Incorporating Dna For Inhibiting Toll Like Receptors And Methods Of Using The Same |
| WO2022164923A1 | Vector Constructs For Delivery Of Nucleic Acids Encoding Therapeutic Anti-Tnf Antibodies And Methods Of Using The Same |
| CA3206107A1 | Vector Constructs For Delivery Of Nucleic Acids Encoding Therapeutic Anti-Tnf Antibodies And Methods Of Using The Same |
| CA3173768A1 | Viral Vector Constructs For Delivery Of Nucleic Acids Encoding Cytokines And Uses Thereof For Treating Cancer |
| CA3174156A1 | Modified Insulin And Glucokinase Nucleic Acids For Treating Diabetes |
| AU2022214822A1 | Vector Constructs For Delivery Of Nucleic Acids Encoding Therapeutic Anti-Tnf Antibodies And Methods Of Using The Same |
| AU2021300450A1 | Modified Insulin And Glucokinase Nucleic Acids For Treating Diabetes |
| BR112022026776A2 | Modified Insulin And Glucokinase Nucleic Acids For The Treatment Of Diabetes |
| HK40084767A | Modified Insulin And Glucokinase Nucleic Acids For Treating Diabetes |
| IL299545A | Modified Insulin And Glucokinase Nucleic Acids For Treating Diabetes |
| MX2023000099A | Modified Insulin And Glucokinase Nucleic Acids For The Treatment Of Diabetes |
| NZ802339A | Vector Constructs For Delivery Of Nucleic Acids Encoding Therapeutic Anti-Tnf Antibodies And Methods Of Using The Same |
| ZA202300430A | Modified Insulin And Glucokinase Nucleic Acids For Treating Diabetes |
| WO2022081776A1 | Viral Vector Constructs For Delivery Of Nucleic Acids Encoding Cytokines And Uses Thereof For Treating Cancer |
| WO2022006551A3 | Modified Insulin And Glucokinase Nucleic Acids For Treating Diabetes |
What are Kriya Therapeutics key innovation segments?
What Technologies are Covered by Kriya Therapeutics?
The chart below distributes patents filed by Kriya Therapeutics